Malignant Digestive System Neoplasm

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including SW837 cell line harboring FBW7 L403fs*34 mutation, were associated with resistance to r… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders … (full text at CIViC)

PMID 26508446 · Lupini et al., 2015 · Open in CIViC

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including LoVo cell line harboring FBW7 R505C mutation, were associated with resistance to regoraf… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including LS411N cell line harboring FBW7 R505H mutation, were associated with resistance to regor… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including HCT-8 cell line harboring FBW7 R658Q mutation, were associated with resistance to regora… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including SW48 cell line harboring FBW7 S668fs*39 mutation, were associated with resistance to re… (full text at CIViC)

PMID 27399335 · Tong et al., 2017 · Open in CIViC

In a retrospective study of 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, FGF19 copy-number gain (defined as ≥5 copies) was detected in 2/6 (33.3%) patients with complete… (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

In a study with a panel of 40 HCC cell lines and 30 HCC PDX model showed that FGF19 expression is a predictive biomarker for H3B-6527. H3B-6527 is a highly selective covalent FGFR4 inhibitor.

PMID 29247039 · Joshi et al., 2017 · Open in CIViC

In a phase 1 trial, patients with hepatocellular carcinoma were treated with selective FGFR4 inhibitor, fisogatinib (BLU-554). For dose escalation, 25 patients received 140 to 900 mg fisogatinib once … (full text at CIViC)

PMID 31575541 · Kim et al., 2019 · Open in CIViC

FGF3/FGF4 amplification was observed in around 2% of HCCs. Although the sample size was relatively small, FGF3/FGF4 amplification, a poorly differentiated histological type, and multiple lung metastas… (full text at CIViC)

PMID 22890726 · Arao et al., 2013 · Open in CIViC

In a retrospective analysis of sorafenib-treated hepatocellular carcinoma, FGF3/FGF4 co-amplification was detected in 3 of 10 evaluable tumors from patients with complete or partial responses and in 0… (full text at CIViC)

PMID 22890726 · Arao et al., 2013 · Open in CIViC

Among 76 patients with refractory metastatic colorectal cancer treated with regorafenib, FGFR1 amplification was identified in three patients (3.9%), and all three achieved a partial response to regor… (full text at CIViC)

PMID 33224274 · Lee et al., 2020 · Open in CIViC

FGFR inhibitor BGJ398 was most effective in a gastric cancer cell line model with high expression of FGFR1 and FGFR2IIIc.

PMID 26637881 · Schmidt et al., 2015 · Open in CIViC

In vitro studies showed efficacy of FGFR inhibitor NVP-BGJ398 in cell lines exhibiting high FGFR1 protein. Three cell lines (SNU-C1, HDC9, HCT116) were analyzed. FGFR1 amplification (24/454, assessed … (full text at CIViC)

PMID 24135816 · Göke et al., 2013 · Open in CIViC

Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored the FGFR1 S602F kinase-domain mutation achieved a complete response. FGFR1 S602F was … (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

In the phase II NCI-MATCH EAY131-K2 trial, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-ACOT11 fusion achieved a partial response to erdafitinib, with a 49.6% maximum reduction in… (full text at CIViC)

PMID 38603650 · Gong et al., 2024 · Open in CIViC

Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 f… (full text at CIViC)

PMID 24122810 · Arai et al., 2014 · Open in CIViC

In the phase II NCI-MATCH EAY131-K2 trial, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-AHCYL1 fusion achieved a partial response to erdafitinib, with a 66.7% maximum reduction in… (full text at CIViC)

PMID 38603650 · Gong et al., 2024 · Open in CIViC

Among 80 patients, FGFR2 amplification was observed in seven cases (11.5%). Patients with FGFR2 amplification had significantly shorter overall survival (OS) than did those without FGFR2 amplification… (full text at CIViC)

PMID 26254407 · Shoji et al., 2015 · Open in CIViC

Xenograft models of SNU-16 human gastric cancer cell lines with FGFR2 amplifications were treated with JNJ-42756493 (erdafitinib). A dose dependent reduction in tumor volume was observed with treatme… (full text at CIViC)

PMID 28341788 · Perera et al., 2017 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 f… (full text at CIViC)

PMID 24122810 · Arai et al., 2014 · Open in CIViC

In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC)

PMID 36652354 · Goyal et al., 2023 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Phase I dose-escalation cohort of patients with advanced solid tumors in which antineoplastic therapy (NCT01703481) was no longer effective, using pan-FGFR inhibitor erdafitinib (JNJ-42756493). Among … (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC)

PMID 36652354 · Goyal et al., 2023 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored FGFR2 M538I achieved a partial response. The same tumor also harbored FGFR4 G665E, pr… (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor erdafitinib (JNJ-42756493). 1 chola… (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor JNJ-42756493. 2 cholangiocarcinoma … (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

In a case report of metastatic cholangiocarcinoma harboring an FGFR2 W290_P307>C (16.25% Variant allele frequency) alteration together with CDH1 Q677fs*7 (23.1% VAF) and CDKN2A/B frameshift mutations … (full text at CIViC)

PMID 38645422 · Aydın et al., 2024 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However,… (full text at CIViC)

PMID 24550739 · Borad et al., 2014 · Open in CIViC

Patients with high FGFR2 expression had an overall survival rate of 72.2,40.6% at 1,3 years (p<0.05) and those with low FGFR2 expression had a 1,3 year survival rate of 92.0,82.8% (p<0.05). The diseas… (full text at CIViC)

PMID 20798558 · Harimoto et al., 2010 · Open in CIViC

FGFR2 over-expression was observed in 75.9 % (n = 107)of the 141 eligible patients and was correlated with perineural invasion (P = 0.005) and inferior tumor regression grading (TRG) (P = 0.009). On u… (full text at CIViC)

PMID 26831663 · Yoon et al., 2016 · Open in CIViC